EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Implementation of an Automated Lipoprotein(a) Assay on a Third-Party Automated Analyzer: Validation, Method Comparison, and Clinical Impact of Formula-Based Mass-to-Molar Conversion

Nerea Sainz-Pastor, Silvia Camos Anguila, Miriam Albéniz Abaigar, Ana Molina, Helena Castellà, Marc Delgado, José Luis Bedini, Rebeca Muñoz, Emilio Ortega, Naira Rico

The Journal of Applied Laboratory Medicine · 2026-11-04 · 11 (6) · 1350-1363

DOI: 10.1093/jalm/jfag122 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Lipoprotein(a) [Lp(a)] is an independent, genetically determined cardiovascular risk factor. Although consensus recommends reporting Lp(a) in molar units using assays with minimized apolipoprotein(a) [apo(a)] isoform size–related bias, some laboratories still use mass units with conversion formulas of uncertain reliability. This study describes the first adaptation and validation of the Roche Tina-quant® Lp(a) Gen.2 assay [TQ-Lp(a)] on the Atellica Solution platform, including method comparison and evaluation of formula-based mass-to-molar conversion. Methods A total of 126 serum samples were analyzed using 3 approaches: Roche TQ-Lp(a) as the molar comparator method, adapted Atellica-TQ-Lp(a), and native Siemens Lp(a) on Atellica CH, which reports results in mg/dL. Siemens mass-based results were converted to nmol/L using the manufacturer’s equation. Analytical performance was assessed according to Spanish Society of Laboratory Medicine recommendations. Method comparison included Passing–Bablok regression, Bland–Altman, and Cohen κ at clinically relevant thresholds. Results Atellica-TQ-Lp(a) demonstrated acceptable precision (CV <6%), excellent linearity (r = 0.99), and adequate sensitivity (limit of quantification, 8 nmol/L). No relevant interference was observed, and stability was maintained for 4 days under refrigerated and frozen conditions. Agreement with the comparator method was high (slope, 0.99; intercept, 3.9 nmol/L; r = 0.99), with minimal constant bias and high categorical concordance (weighted κ = 0.98). In contrast, formula-derived values showed proportional bias (slope, 1.27), moderate agreement (weighted κ = 0.78), and frequent upward reclassification at ≥125 nmol/L. Conclusions The Roche Tina-quant® Lp(a) Gen.2 assay can be implemented on Atellica CH to report Lp(a) in nmol/L with high analytical comparability to the Roche/cobas implementation. Fixed mg/dL-to-nmol/L conversion formulas introduce systematic bias and clinically relevant misclassification.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →